Jordan 2017 Medical Device Registration Guidelines: Procedures, Grouping and Objections

1. Key takeaways

The 2017 Registration Guidelines for Medical Devices is the operational-layer text of the Jordanian registration procedure. GRZAN’s conclusion is that the importation directives answer “whether you can import” while this guideline answers “how you register”, and neither can substitute for the other.

The second conclusion is that the guideline, together with the importation directives, the 2019 circulation criteria and the 2011 GMP guidelines, forms a set of four. A company’s registration actions in Jordan must simultaneously satisfy all four documents; a single missing piece will show up as a documentary gap at some stage of the process.

The third conclusion is that the guideline has been in force for more than eight years, and during that period JFDA has made multiple adjustments through circulars. When using the guideline, companies must search the current JFDA circulars as an overlay, and in particular the pre-condition import requirement for Class IIb devices introduced by Circular No. 54863/1/5 of 9 October 2025.

• The 2017 guideline is the operational text; the directives decide importability, the guideline decides registrability.
• Four documents form the registration set: directives, guideline, circulation criteria and GMP guidelines.
• Family and system grouping are the two recognised routes for consolidating registration units.
• Circular adjustments must always be layered on top of the guideline text before submission.

The four-document set works only when used in the right order. The directives decide whether import is possible at all, the guideline prescribes how the registration file is built, the circulation criteria govern what happens after approval, and the GMP guidelines govern the production side that stands behind the file. Reading them in that sequence, and layering the current circulars on top, turns a scattered body of texts into a single workable procedure.

2. Legal basis

The registration procedure rests on the following instruments.

Provision numbers are subject to the Arabic original texts issued in the Jordanian Official Gazette and by JFDA.

3. Expert insights

Insight 1: the guideline establishes two routes for grouped registration. Jordan permits registration units to be organised by family grouping and by system grouping. Family grouping requires the same product owner, the same risk class, a common intended purpose, common design and manufacturing processes, and variation only within permitted ranges. System grouping requires the same product owner, combination use to achieve a common intended purpose, compatibility among the components, and sale under a single system name or an indication on the labels, instructions, manuals or catalogues of each component that they are intended for use together. These two rules are the key instruments for compressing the number of registrations.

Insight 2: the guideline and the directives complement each other on the document list. The directives give the general conditions and the basic document list for first importation, while the guideline details the depth requirements for technical documentation, clinical data, risk management and quality management system documents. When preparing a dossier, companies should follow the union of the two documents. Building that union once, at dossier start, avoids the familiar pattern in which a document demanded at review exists in the company but was never placed in the submission.

Insight 3: the guideline’s objection procedure clauses match the fee schedule. An applicant has the right to file an objection within 30 working days of receiving notice of the relevant decision of the devices committee; the JFDA fee schedule sets the fee for an objection application at 100 JOD. The procedure and the fee match at both ends, showing that the objection is an institutionally designed remedy in the Jordanian registration system rather than an ad hoc arrangement.

Insight 4: gaps in the guideline are filled by circulars. JFDA circulars carry immediate executive force in practice. GRZAN recommends that companies maintain a two-layer document register of “guideline plus circulars” and run a circular search before every submission.

4. Practical recommendations

• Build the dossier around the guideline as the skeleton, check the document list against the importation directives, check warehousing and circulation conditions against the circulation criteria, and check production-side documents against the GMP guidelines.
• Consider grouped registration first. For product lines with many models, family grouping can significantly reduce the number of registrations and the fees, but all four conditions must be satisfied simultaneously.
• Complete a circular search before submission. Focus on whether the intended classification has acquired any new front-end requirement or testing requirement.
• Assign one owner inside the company to maintain the guideline-plus-circular register, so that the search before each submission is systematic rather than ad hoc.

5. Verification checklist

• □ Obtain the version of the 2017 registration guidelines currently in force
• □ Check whether the product satisfies the four conditions of family grouping
• □ Check whether the product satisfies the conditions of system grouping
• □ Check the document list against the importation directives and warehousing conditions against the circulation criteria
• □ Confirm the intended grouping route in writing before dossier compilation, since the grouping choice shapes the structure of the whole file
• □ Search current JFDA circulars to confirm no new front-end requirement applies
• □ Record the objection window (30 working days) and the fee (100 JOD) for devices committee decisions
• □ Re-verify the cited provision numbers against the Arabic original texts of the Official Gazette

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Jordanian market. Our team manages Jordan Food and Drug Administration (JFDA) registrations, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com